Efficient delivery of antibody into living cells using a novel HVJ envelope vector system

Kondo, Yoshitaka; Fushikida, Kuni; Fujieda, Takayuki; Sakai, Kimie; Miyata, Keizo; Kato, Fuminori; Kato, Masanari

doi:10.1016/j.jim.2007.12.008

Cited by 32 publications

(23 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of monoclonal antibodies is problematic when it is necessary to target intracellular proteins because of a lack of accessibility. However, a new method for the intracellular delivery of antibodies has been developed recently that uses a novel hemagglutinating virus of Japan envelope vector system (Kondo et al, 2008). The hemagglutinating virus of Japan envelope is an inactivated Sendai virus particle that can fuse to the external membrane of a cell and thereby deliver a variety of molecules into living mammalian cells (Kondo et al, 2008).…”

Section: A Pharmacological Modulation Of Nuclear Importmentioning

confidence: 99%

“…However, a new method for the intracellular delivery of antibodies has been developed recently that uses a novel hemagglutinating virus of Japan envelope vector system (Kondo et al, 2008). The hemagglutinating virus of Japan envelope is an inactivated Sendai virus particle that can fuse to the external membrane of a cell and thereby deliver a variety of molecules into living mammalian cells (Kondo et al, 2008). This new method could hold great promise for the future to deliver monoclonal antibodies that selectively block the NPC.…”

Section: A Pharmacological Modulation Of Nuclear Importmentioning

confidence: 99%

See 1 more Smart Citation

Therapeutic Targeting of Nuclear Protein Import in Pathological Cell Conditions

Chahine

Pierce

2009

Pharmacol Rev

View full text Add to dashboard Cite

Section: A Pharmacological Modulation Of Nuclear Importmentioning

confidence: 99%

Section: A Pharmacological Modulation Of Nuclear Importmentioning

confidence: 99%

Therapeutic Targeting of Nuclear Protein Import in Pathological Cell Conditions

Chahine

Pierce

2009

Pharmacol Rev

View full text Add to dashboard Cite

“…Recently, we have achieved rather efficient in vivo siRNA delivery by using the hemagglutinating virus of Japan envelope (HVJ-E), which is an inactivated Sendai virus particle that was developed as a drug delivery vector. [11][12][13] Furthermore, HVJ-E itself induces diverse anti-tumor immunity, including dendritic cell maturation, NK cell activation, cytotoxic T lymphocyte (CTL) induction and regulatory T-cell suppression. [14][15][16] Therefore, therapeutic molecules, such as oligonucleotides, plasmids or siRNA, that are packaged into HVJ-E are expected to have increased anti-cancer activities.…”

Section: Introductionmentioning

confidence: 99%

The combination of chemotherapy with HVJ-E containing Rad51 siRNA elicited diverse anti-tumor effects and synergistically suppressed melanoma

et al. 2011

View full text Add to dashboard Cite

Dacarbazine (DTIC) is one of the most popular alkylating agents used for the treatment of malignant melanoma. DTIC induces apoptosis of melanoma cells via double-strand breaks (DSBs). Melanoma cells, however, tend to increase their expression of DNA repair molecules in order to be resistant to DTIC. Here, we show that DTIC increases expression of Rad51, but not Ku70, in a cultured B16-F10 mouse melanoma cell line in dose-and time-dependent manners. On introducing Rad51 short interfering RNA (siRNA) with the hemagglutinating virus of Japan envelope (HVJ-E) to B16-F10 cells, DSBs induced by DTIC treatment were not efficiently repaired and resulted in enhanced apoptotic cell death. Colony formation of B16-F10 cells that received Rad51 siRNA was significantly decreased by DTIC treatment as compared with cells that received scramble siRNA. In melanoma-bearing mice, the combination of three intratumoral injections of HVJ-E containing Rad51 siRNA and five intraperitoneal injections of DTIC at a clinical dose synergistically suppressed the tumors. Moreover, HVJ-E demonstrated anti-tumor immunity by inducing cytotoxic T lymphocytes to B16-F10 cells on administration of DTIC. These results suggest that the combination of chemotherapy with HVJ-E containing therapeutic molecules will provide a promising therapeutic strategy for patients bearing malignant tumors resistant to chemotherapeutic agents.

show abstract

“…Recent strategies for intracellular delivery of functional proteins include the use of liposomes to encapsulate both proteins and genes for intracellular delivery (2), antibody delivery via protein transduction domains (PTDs; ref. (3), membrane receptors and transport signals (4–6), viral vectors (7), microinjection (8), and electroporation (9). However, each of these methods lacks convenience and effectiveness, and they are often compromised by cellular toxicity and stress.…”

mentioning

confidence: 99%

Fully synthetic polymer vesicles for intracellular delivery of antibodies in live cells

et al. 2012

View full text Add to dashboard Cite

There is an emerging need both in pharmacology and within the biomedical industry to develop new tools to target intracellular mechanisms. The efficient delivery of functionally active proteins within cells is potentially a powerful research strategy, especially through the use of antibodies. In this work, we report on a nanovector for the efficient encapsulation and delivery of antibodies into live cells with no significant loss of cell viability or any deleterious effect on cell metabolic activity. This delivery system is based on poly[2-(methacryloyloxy)ethyl phosphorylcholine]-block-[2-(diisopropylamino)ethyl methacrylate] (PMPC-PDPA), a pH-sensitive diblock copolymer that self-assembles to form nanometer-sized vesicles, also known as polymersomes, at physiological pH. Polymersomes can successfully deliver relatively high antibody payloads within different types of live cells. We demonstrate that these antibodies can target their respective epitope showing immunolabeling of γ-tubulin, actin, Golgi protein, and the transcription factor NF-κB in live cells. Finally, we demonstrate that intracellular delivery of antibodies can control specific subcellular events, as well as modulate cell activity and proinflammatory processes.

show abstract

Efficient delivery of antibody into living cells using a novel HVJ envelope vector system

Cited by 32 publications

References 12 publications

Therapeutic Targeting of Nuclear Protein Import in Pathological Cell Conditions

Therapeutic Targeting of Nuclear Protein Import in Pathological Cell Conditions

The combination of chemotherapy with HVJ-E containing Rad51 siRNA elicited diverse anti-tumor effects and synergistically suppressed melanoma

Fully synthetic polymer vesicles for intracellular delivery of antibodies in live cells

Contact Info

Product

Resources

About